Creative Planning Has $4.24 Million Stock Position in Illumina, Inc. $ILMN

Creative Planning lifted its holdings in Illumina, Inc. (NASDAQ:ILMN) by 144.8% during the 2nd quarter, HoldingsChannel reports. The fund owned 44,386 shares of the life sciences company’s stock after acquiring an additional 26,253 shares during the quarter. Creative Planning’s holdings in Illumina were worth $4,235,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. SG Americas Securities LLC grew its position in shares of Illumina by 408.7% during the 2nd quarter. SG Americas Securities LLC now owns 6,933 shares of the life sciences company’s stock worth $661,000 after purchasing an additional 5,570 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its stake in shares of Illumina by 7.4% in the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 40,672 shares of the life sciences company’s stock valued at $3,881,000 after buying an additional 2,808 shares during the period. Jacksonville Wealth Management LLC acquired a new stake in Illumina during the second quarter worth approximately $236,000. Police & Firemen s Retirement System of New Jersey increased its stake in Illumina by 4.4% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 24,161 shares of the life sciences company’s stock worth $2,305,000 after acquiring an additional 1,029 shares during the period. Finally, Geode Capital Management LLC raised its holdings in Illumina by 0.7% in the 2nd quarter. Geode Capital Management LLC now owns 2,869,187 shares of the life sciences company’s stock valued at $272,921,000 after acquiring an additional 21,342 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on ILMN. Wall Street Zen raised Illumina from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Royal Bank Of Canada set a $124.00 price objective on shares of Illumina in a research note on Tuesday, September 2nd. TD Cowen raised their target price on shares of Illumina from $110.00 to $115.00 and gave the company a “hold” rating in a report on Friday, October 31st. Daiwa Capital Markets downgraded shares of Illumina from an “outperform” rating to a “neutral” rating and set a $94.00 price target for the company. in a report on Tuesday, August 12th. Finally, Evercore ISI increased their price target on shares of Illumina from $132.00 to $142.00 and gave the stock an “outperform” rating in a research report on Friday, October 31st. Five analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $115.00.

Insider Buying and Selling at Illumina

In other Illumina news, Director Scott Gottlieb acquired 500 shares of Illumina stock in a transaction that occurred on Monday, November 3rd. The shares were bought at an average price of $122.13 per share, with a total value of $61,065.00. Following the completion of the purchase, the director directly owned 12,523 shares in the company, valued at $1,529,433.99. This trade represents a 4.16% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. 2.60% of the stock is currently owned by corporate insiders.

Illumina Stock Performance

NASDAQ:ILMN opened at $123.85 on Friday. The stock’s 50-day moving average is $105.22 and its 200-day moving average is $97.37. Illumina, Inc. has a 1-year low of $68.70 and a 1-year high of $153.06. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.66. The stock has a market cap of $18.92 billion, a P/E ratio of 15.68, a price-to-earnings-growth ratio of 2.34 and a beta of 1.42.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, October 30th. The life sciences company reported $1.34 EPS for the quarter, topping the consensus estimate of $1.16 by $0.18. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The business had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same period last year, the company earned $1.14 EPS. The firm’s revenue was up .4% compared to the same quarter last year. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. Equities research analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.